Dallas, TX, April 29, 2026 (GLOBE NEWSWIRE) -- PatentVest today released its latest PatentVest Pulse: “The Last 20%: Retatrutide, the Glucagon Paradox, and the Race to Own Surgery-Level Weight Loss Without Surgery.”
In April 2026, Eli Lilly’s retatrutide delivered 28.7% mean weight loss, the first non-surgical therapy to match bariatric outcomes.
But the milestone didn’t end the race. It changes it.
Everyone is focused on the 28.7%,” said Will Rosellini - Chief IP Officer at PatentVest.
“But that number is just the entry point. Once the mechanism works, the question shifts from who can build it to who controls it, and that’s where most teams are underprepared.”
Across the landscape:
- Novo Nordisk is building across multiple triple-agonist assets
- Pfizer has entered through acquisition
- Hanmi is advancing the only clinical-stage small-molecule triple
- Innovent, Hengrui, and multiple Chinese sponsors are scaling pipeline depth
- Sanofi holds the largest IP position without a disclosed asset
27 programs. One validated mechanism.
What shifts now:
The question is no longer who can build these drugs.
It’s:
- Who can operate around the IP
- Who gets blocked
- And who ends up paying to participate
Because 28.7% doesn’t hold in the real world. And the gap between trial results and actual outcomes becomes the real battleground.
We call it:
The Last 20%.
This report maps:
- The full pipeline
- The deal layer shaping access
- And the IP structure that will define who captures value
About PatentVest
PatentVest is where intellectual property strategy meets execution. We partner with innovators and in-house legal teams to turn patent portfolios into value creation, combining seasoned IP counsel, analyst-driven intelligence, and a technology stack purpose-built for modern IP work. All at Better Quality and Greater Efficiency than Big Law. Whether you're protecting a breakthrough, evaluating a target, or building toward a liquidity event, our integrated Strategy and Legal Services help you move with clarity and speed. Let's talk about what your IP could be doing for you.
Reach out to explore how PatentVest can support your next move.
Media Contact:
For more information or inquiries, please contact [email protected].